You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK (GenomeWeb) – The US Food and Drug Administration yesterday approved the second tumor-agnostic precision oncology drug targeting NTRK gene fusions, called Vitrakvi (larotrectinib).
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.